Compare FNWD & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWD | SPRO |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.0M | 135.8M |
| IPO Year | N/A | 2017 |
| Metric | FNWD | SPRO |
|---|---|---|
| Price | $38.74 | $2.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $34.00 | $5.00 |
| AVG Volume (30 Days) | 19.5K | ★ 225.1K |
| Earning Date | 01-26-2026 | 11-13-2025 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $66,563,999.00 | $40,549,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.03 | N/A |
| P/E Ratio | $19.87 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.12 | $0.51 |
| 52 Week High | $39.99 | $3.22 |
| Indicator | FNWD | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 59.15 | 53.37 |
| Support Level | $34.12 | $2.31 |
| Resistance Level | $35.36 | $2.66 |
| Average True Range (ATR) | 1.17 | 0.10 |
| MACD | 0.32 | -0.01 |
| Stochastic Oscillator | 75.54 | 40.85 |
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.